U.S. same-store sales grew by 2.6%, missing the 3.8% target projected by market analysts. This performance marks a departure from the company’s recent history of consistently topping expectations. The average transaction value rose by only 1.1%, a sharp deceleration compared to the 3.1% increase recorded during the same period last year.
Pharmacy sales also faced headwinds, hampered by the Inflation Reduction Act's Maximum Fair Price program. When excluding this specific regulatory impact, core U.S. comparable sales showed a more resilient 3.4% rise. CEO John Furner remains focused on offsetting these pressures by doubling down on price reductions and scaling the company’s advertising and digital commerce ventures to maintain market share.





Comments (0)
No comments yet. Be the first!